Flexible dosing of montelukast for treatment of seasonal allergic rhinitis: Morning or evening

Adelsberg, Janet van; Philip, George; Menten, Joris; Malice, Marie Pierre; Reiss, T. F.

doi:10.1016/s0091-6749(03)80467-0

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Urinary LTE 4 levels were found to be significantly higher in patients with AR with severe nasal congestion [72] and less evident in patients with mild congestion [73]. The improvement in nasal congestion following treatment with leukotriene modifiers, measured either by symptom scores [46,[52][53][54][55][56]74] or airway resistance [61,67,68] in clinical trials of patients with AR further implicates CysLTs in mediating nasal congestion. It should be noted that, because of the presence of both CysLT 1 and CysLT 2 receptors in nasal vasculature, and because stimulation of the CysLT 2 receptor appears to increase vascular permeability [24], antagonism of both receptors may offer stronger effects against nasal congestion in AR.…”

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 96%

“…After allergen challenge, the timing of LTC 4 release has been shown to correlate with sneezing [30,33]. CysLTs do not directly induce sneezing and pruritus [50,51]; however, CysLTs may have an indirect effect on sneezing, as indicated by the reduction of sneezing with zafirlukast [52] and montelukast [46,[53][54][55][56][57], both leukotriene receptor antagonists, in clinical trials of patients with AR.…”

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 99%

“…Pranlukast improved daytime symptoms [75], and zafirlukast improved nasal congestion, sneezing, rhinorrhea, and itchy nose, throat, and palate, although no clear dose-response could be generated [52]. Montelukast has been shown to improve daytime symptoms (congestion, rhinorrhea, sneezing, and nasal pruritus), night-time symptoms (difficulty to sleep, awakenings, and congestion upon awakening), daytime eye symptoms (tearing, itchy, red, and puffy eyes), and quality of life [53][54][55][56].…”

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 99%

“…In clinical studies, the leukotriene receptor antagonist montelukast reduced peripheral blood eosinophil numbers in adults [53][54][55][56] and children [61,121] with AR. Taken together, the effects of CysLTs on eosinophil differentiation, maturation, proliferation, adhesion molecule expression, migration, survival, and activation described above are consistent with a role of these mediators in local and systemic allergic inflammation.…”

Section: Steps 4 and 5: Migration And Chemoattractionmentioning

confidence: 99%

“…Allergen-induced rhinitis and clinical rhinitis outcomes affected by cysteinyl leukotrienes (CysLTs) CysLTs levels in patients with allergic rhinitis following allergen challenge[30] Significantly improved with LTRA in clinical studies of patients with allergic rhinitis[46,[52][53][54][55][56]61] RhinorrheaSignificantly worsened with intranasal CysLT application[31,50] Significantly improved with LTRA in studies of patients with allergic rhinitis following allergen challenge[67] Significantly improved with LTRA in clinical studies of patients with allergic rhinitis[46, 52-56, 61, 68] Nasal pruritus Significantly improved with LTRA in clinical studies of patients with allergic rhinitis [53, 54, 61, 62] CongestionSignificantly worsened with intranasal CysLT application[31,50,51,204,205] …”

mentioning

confidence: 99%

See 4 more Smart Citations

Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitis

Peters‐Golden

Gleason

Togias

2006

Clin Experimental Allergy

195

150

View full text Add to dashboard Cite

Summary Cysteinyl leukotrienes (CysLTs) are a family of inflammatory lipid mediators synthesized from arachidonic acid by a variety of cells, including mast cells, eosinophils, basophils, and macrophages. This article reviews the data for the role of CysLTs as multi‐functional mediators in allergic rhinitis (AR). We review the evidence that: (1) CysLTs are released from inflammatory cells that participate in AR, (2) receptors for CysLTs are located in nasal tissue, (3) CysLTs are increased in patients with AR and are released following allergen exposure, (4) administration of CysLTs reproduces the symptoms of AR, (5) CysLTs play roles in the maturation, as well as tissue recruitment, of inflammatory cells, and (6) a complex inter‐regulation between CysLTs and a variety of other inflammatory mediators exists.

show abstract

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 96%

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 99%

Section: Cyslts Are Elevated In Studiesmentioning

confidence: 99%

Section: Steps 4 and 5: Migration And Chemoattractionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitis

Peters‐Golden

Gleason

Togias

2006

Clin Experimental Allergy

195

150

View full text Add to dashboard Cite

show abstract

Circadian Variation in Efficacy of Medications

Walton

Walker

Bumgarner

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Although much has been learned about circadian clocks and rhythms over the past few decades, translation of this foundational science underlying the temporal regulation of physiology and behavior to clinical applications has been slow. Indeed, acceptance of the modern study of circadian rhythms has been blunted because the phenomenology of cyclic changes had to counteract the 20th century dogma of homeostasis in the biological sciences and medicine. We are providing this review of clinical data to highlight the emerging awareness of circadian variation in efficacy of medications for physicians, clinicians, and pharmacists. We are suggesting that gold‐standard double‐blind clinical studies should be conducted to determine the best time of day for optimal effectiveness of medications; also, we suggest that time of day should be tracked and reported as an important biological variable in ongoing clinical studies hereafter. Furthermore, we emphasize that time of day is, and should be considered, a key biological variable in research design similar to sex. In common with biomedical research data that have been historically strongly skewed toward the male sex, most pharmaceutical data have been skewed toward morning dosing without strong evidence that this is the optimal time of efficacy.

show abstract

Miejsce leukotrienów w patofizjologii astmy oskrzelowej. Konieczność leczenia przeciwleukotrienowego

Fal

Kopeć²

2010

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Astma jest przewlekłą chorobą zapalną dróg oddechowych, w której uczestniczy wiele komórek zapalnych i mediatorów. Obecnie rekomenduje się wziewne glikokortykosteroidy, jako najbardziej skuteczne leki przeciwzapalne dostępne w leczeniu astmy. Niektórzy pacjenci nie osiągają jednak kontroli choroby, mimo stosowania dużych dawek wziewnych glikokortykosteroidów w monoterapii lub skojarzeniu z długodziałającymi beta2-mimetykami. W przebiegu zapalenia astmatycznego ulegają aktywacji różne szlaki komórkowe. Szczególnie ważna jest ścieżka prowadząca do syntezy leukotrienów. Leukotrieny, takie jak leukotrien C4, D4, E4 (zwane leukotrienami cysteinylowymi), są znane z silnego działania prozapalnego oraz kurczącego oskrzela. Leukotrieny zwiększają przepuszczalność naczyń krwionośnych i produkcję śluzu w oskrzelach oraz mogą przyczyniać się do niekorzystnej przebudowy oskrzeli (remodelingu). Ich działanie chemotaktyczne na różne komórki zapalne (eozynofile, mastocyty, neutrofile) przyczynia się do podtrzymywania przewlekłego zapalenia w drogach oddechowych. Te biologiczne działania leukotrienów wskazują na ich ważną rolę w patogenezie astmy. Chociaż wziewne glikokortykosteroidy hamują wiele składowych zapalenia astmatycznego, to nie wpływają one na syntezę leukotrienów. W związku z tym dodatkowa terapia za pomocą antagonistów leukotrienów może okazać się korzystna dla tej grupy astmatyków. Dobrze udokumentowano działanie przeciwzapalne i bronchoprotekcyjne antyleukotrienów. Są one szczególnie skuteczne u pacjentów z astmą aspirynową i tych ze współistniejącym alergicznym nieżytem nosa. Leki antyleukotrienowe są także stosowane w zapobieganiu skurczowi oskrzeli wywołanym wysiłkiem i zimnym powietrzem. Mniej skuteczne w monoterapii, jako terapia dodana do wziewnych glikokortykosteroidów, poprawiają kontrolę astmy, powodując zmniejszenie liczby zaostrzeń choroby, zużycia krótkodziałających beta2-mimetyków oraz poprawę funkcji płuc. Artykuł podsumowuje obecną wiedzę na temat roli leukotrienów w patogenezie astmy oraz aspektów klinicznych terapii lekami antyleukotrienowymi.

show abstract

Flexible dosing of montelukast for treatment of seasonal allergic rhinitis: Morning or evening

Cited by 3 publications

References 0 publications

Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitis

Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitis

Circadian Variation in Efficacy of Medications

Miejsce leukotrienów w patofizjologii astmy oskrzelowej. Konieczność leczenia przeciwleukotrienowego

Contact Info

Product

Resources

About